{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:59:48Z","timestamp":1787695188393,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002329","name":"Bundesamt f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["10.001359\/204.0001\/-738"],"award-info":[{"award-number":["10.001359\/204.0001\/-738"]}],"id":[{"id":"10.13039\/501100002329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018234","name":"Inselspital, Universit\u00e4tsspital Bern","doi-asserted-by":"publisher","award":["Departmental Research Grant"],"award-info":[{"award-number":["Departmental Research Grant"]}],"id":[{"id":"10.13039\/100018234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s13318-025-00941-8","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T01:20:32Z","timestamp":1743902432000},"page":"229-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic\/Pharmacodynamic Modeling of the Acute Heart Rate Effects of Delta-9 Tetrahydrocannabinol and Its Major Metabolites After Intravenous Injection in Healthy Volunteers"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0256-8535","authenticated-orcid":false,"given":"W. R.","family":"Wolowich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Theiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-8529","authenticated-orcid":false,"given":"Maren","family":"Kleine-Brueggeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"issue":"4","key":"941_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"F Grotenhermen","year":"2003","unstructured":"Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327\u201360.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"941_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13318-019-00559-7","volume":"44","author":"WR Wolowich","year":"2019","unstructured":"Wolowich WR, et al. Minimal physiologically based pharmacokinetic model of intravenously and orally administered delta-9-tetrahydrocannabinol in healthy volunteers. Eur J Drug Metab Pharmacokinet. 2019;44(5):691\u2013711.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"941_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107641","volume":"205","author":"B Brands","year":"2019","unstructured":"Brands B, et al. Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. Drug Alcohol Depend. 2019;205: 107641.","journal-title":"Drug Alcohol Depend"},{"key":"941_CR4","doi-asserted-by":"publisher","DOI":"10.1089\/can.2024.0030","author":"SA Limbacher","year":"2024","unstructured":"Limbacher SA, et al. Dose of product or product concentration: a comparison of change in heart rate by THC concentration for participants using cannabis daily and occasionally. Cannabis Cannabinoid Res. 2024. https:\/\/doi.org\/10.1089\/can.2024.0030.","journal-title":"Cannabis Cannabinoid Res."},{"key":"941_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.drugalcdep.2017.02.003","volume":"175","author":"MN Newmeyer","year":"2017","unstructured":"Newmeyer MN, et al. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration. Drug Alcohol Depend. 2017;175:67\u201376.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"941_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","volume":"269","author":"N Solowij","year":"2019","unstructured":"Solowij N, et al. A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):17\u201335.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"8","key":"941_CR7","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0735-1097(23)02129-0","volume":"81","author":"I Paranjpe","year":"2023","unstructured":"Paranjpe I, et al. Association of cannabis use disorder with risk of coronary artery disease: a mendelian randomization study. J Am College Cardiol. 2023;81(8):1685\u20131685.","journal-title":"J Am College Cardiol"},{"key":"941_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40119-017-0102-x","volume":"7","author":"A Singh","year":"2018","unstructured":"Singh A, et al. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 2018;7:45\u201359.","journal-title":"Cardiol Ther"},{"issue":"1","key":"941_CR9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.amjcard.2013.09.042","volume":"113","author":"G Thomas","year":"2014","unstructured":"Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187\u201390.","journal-title":"Am J Cardiol"},{"issue":"3","key":"941_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jacc.2019.11.025","volume":"75","author":"EM DeFilippis","year":"2020","unstructured":"DeFilippis EM, et al. Marijuana use in patients with cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol. 2020;75(3):320\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"941_CR11","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.jacc.2018.02.047","volume":"71","author":"EM DeFilippis","year":"2018","unstructured":"DeFilippis EM, et al. Cocaine and marijuana use among young adults with myocardial infarction. J Am Coll Cardiol. 2018;71(22):2540\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"941_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030178","volume":"13","author":"AM Jeffers","year":"2024","unstructured":"Jeffers AM, et al. Association of cannabis use with cardiovascular outcomes among US adults. J Am Heart Assoc. 2024;13(5): e030178.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"941_CR13","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1161\/CIR.0000000000000883","volume":"142","author":"RL Page","year":"2020","unstructured":"Page RL, et al. Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2020;142(10):e131\u201352.","journal-title":"Circulation"},{"issue":"4","key":"941_CR14","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1007\/s40429-022-00429-4","volume":"9","author":"CA Zamarripa","year":"2022","unstructured":"Zamarripa CA, Vandrey R, Spindle TR. Factors that impact the pharmacokinetic and pharmacodynamic effects of cannabis: a review of human laboratory studies. Curr Addict Rep. 2022;9(4):608\u201321.","journal-title":"Curr Addict Rep"},{"issue":"7","key":"941_CR15","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0269881108089870","volume":"22","author":"A Strougo","year":"2008","unstructured":"Strougo A, et al. Modelling of the concentration\u2014effect relationship of THC on central nervous system parameters and heart rate\u2014insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. J Psychopharmacol. 2008;22(7):717\u201326.","journal-title":"J Psychopharmacol"},{"issue":"4043","key":"941_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.177.4043.62","volume":"177","author":"L Lemberger","year":"1972","unstructured":"Lemberger L, Crabtree RE, Rowe HM. 11-Hydroxy-\u03949-tetrahydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science. 1972;177(4043):62\u20134.","journal-title":"Science"},{"issue":"2","key":"941_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/1872312811206020102","volume":"6","author":"M Joerger","year":"2012","unstructured":"Joerger M, et al. Single-dose pharmacokinetics and tolerability of oral delta-9-tetrahydrocannabinol in patients with amyotrophic lateral sclerosis. Drug Metab Lett. 2012;6(2):102\u20138.","journal-title":"Drug Metab Lett"},{"key":"941_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/JPR.S113138","volume":"9","author":"BL Wilsey","year":"2016","unstructured":"Wilsey BL, et al. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. J Pain Res. 2016;9:587\u201398.","journal-title":"J Pain Res"},{"issue":"6","key":"941_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","volume":"30","author":"L Zhang","year":"2003","unstructured":"Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30(6):387\u2013404.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"941_CR20","unstructured":"Gabrielsson J and Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 2001."},{"issue":"6","key":"941_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1472-8206.2008.00633.x","volume":"22","author":"S Goutelle","year":"2008","unstructured":"Goutelle S, et al. The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol. 2008;22(6):633\u201348.","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"941_CR22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716\u201323.","journal-title":"IEEE Trans Autom Control"},{"issue":"1","key":"941_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18433\/J3GP53","volume":"17","author":"C Louizos","year":"2014","unstructured":"Louizos C, et al. Understanding the hysteresis loop conundrum in pharmacokinetic\/pharmacodynamic relationships. J Pharm Pharm Sci. 2014;17(1):34\u201391.","journal-title":"J Pharm Pharm Sci"},{"key":"941_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369.","journal-title":"AAPS J"},{"issue":"2","key":"941_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3390\/molecules29020410","volume":"29","author":"AK Al-Khazaleh","year":"2024","unstructured":"Al-Khazaleh AK, et al. The Neurotherapeutic Arsenal in Cannabis sativa: insights into anti-neuroinflammatory and neuroprotective activity and potential entourage effects. Molecules. 2024;29(2):410.","journal-title":"Molecules"},{"issue":"4","key":"941_CR26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/cpt1979254440","volume":"25","author":"NL Benowitz","year":"1979","unstructured":"Benowitz NL, et al. Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther. 1979;25(4):440\u20136.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"941_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.tips.2012.03.002","volume":"33","author":"F Montecucco","year":"2012","unstructured":"Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci. 2012;33(6):331\u201340.","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"941_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10286-023-00993-3","volume":"33","author":"M Nardone","year":"2023","unstructured":"Nardone M, et al. Inhalation of THC-containing cannabis selectively diminishes cardiac autonomic function in humans. Clin Auton Res. 2023;33(6):919\u201322.","journal-title":"Clin Auton Res"},{"key":"941_CR29","doi-asserted-by":"publisher","first-page":"E461","DOI":"10.1208\/aapsj070246","volume":"7","author":"S Girgis","year":"2005","unstructured":"Girgis S, et al. Pharmacodynamic parameter estimation: population size versus number of samples. AAPS J. 2005;7:E461\u20136.","journal-title":"AAPS J"},{"issue":"6","key":"941_CR30","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1111\/bcp.13225","volume":"83","author":"M Gonz\u00e1lez-Sales","year":"2017","unstructured":"Gonz\u00e1lez-Sales M, et al. Modelling the dose\u2013response relationship: the fair share of pharmacokinetic and pharmacodynamic information. Br J Clin Pharmacol. 2017;83(6):1240\u201351.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"941_CR31","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/j.1476-5381.2011.01364.x","volume":"163","author":"AC Howlett","year":"2011","unstructured":"Howlett AC, et al. Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol. 2011;163(7):1329\u201343.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"941_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2019.03.009","volume":"1867","author":"S-L Puhl","year":"2020","unstructured":"Puhl S-L. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia. Biochimica et Biophysica Acta (BBA)-Mol Cell Res. 2020;1867(3): 118462.","journal-title":"Biochimica et Biophysica Acta (BBA)-Mol Cell Res"},{"issue":"4","key":"941_CR33","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/bcp.12852","volume":"81","author":"Z Guan","year":"2016","unstructured":"Guan Z, et al. Pharmacokinetic\/pharmaco\u2013dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on \u03949-tetrahydrocannabinol challenge tests. Br J Clin Pharmacol. 2016;81(4):713\u201323.","journal-title":"Br J Clin Pharmacol"},{"key":"941_CR34","first-page":"1","volume-title":"Cannabis and cannabinoid-based medicines in cancer care: a comprehensive guide to medical management","author":"MP Davis","year":"2022","unstructured":"Davis MP. Overview of the endocannabinoid system and endocannabinoidome. In: Cannabis and cannabinoid-based medicines in cancer care: a comprehensive guide to medical management. Springer; 2022. p. 1\u201340."},{"issue":"11","key":"941_CR35","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/bcp.13635","volume":"84","author":"Z Liu","year":"2018","unstructured":"Liu Z, Martin JH. Gaps in predicting clinical doses for cannabinoids therapy: overview of issues for pharmacokinetics and pharmacodynamics modelling. Br J Clin Pharmacol. 2018;84(11):2483\u20137.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"941_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1021\/js950067y","volume":"85","author":"S Dutta","year":"1996","unstructured":"Dutta S, Matsumoto Y, Ebling WF. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci. 1996;85(2):232\u20139.","journal-title":"J Pharm Sci"},{"issue":"1","key":"941_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1365-2125.2012.04164.x","volume":"74","author":"LE Klumpers","year":"2012","unstructured":"Klumpers LE, et al. Novel \u03949-tetrahydrocannabinol formulation Namisol\u00ae has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol. 2012;74(1):42\u201353.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"941_CR38","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/clinchem\/hvaa113","volume":"66","author":"EL Karschner","year":"2020","unstructured":"Karschner EL, Swortwood-Gates MJ, Huestis MA. Identifying and quantifying cannabinoids in biological matrices in the medical and legal cannabis era. Clin Chem. 2020;66(7):888\u2013914.","journal-title":"Clin Chem"},{"key":"941_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.114987","volume":"220","author":"N La Maida","year":"2022","unstructured":"La Maida N, et al. Recent challenges and trends in forensic analysis: \u03949-THC isomers pharmacology, toxicology and analysis. J Pharm Biomed Anal. 2022;220: 114987.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"941_CR40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.vascn.2014.05.004","volume":"70","author":"A Caruso","year":"2014","unstructured":"Caruso A, et al. Translational PK\/PD modeling for cardiovascular safety assessment of drug candidates: methods and examples in drug development. J Pharmacol Toxicol Methods. 2014;70(1):73\u201385.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"3","key":"941_CR41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/psp4.18","volume":"4","author":"T Collins","year":"2015","unstructured":"Collins T, et al. Modeling and simulation approaches for cardiovascular function and their role in safety assessment. CPT Pharmacometrics Syst Pharmacol. 2015;4(3):175\u201388.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"941_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1023\/B:JOPA.0000034404.86036.72","volume":"31","author":"J Ribbing","year":"2004","unstructured":"Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn. 2004;31(2):109\u201334.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"941_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13125","volume":"27","author":"TR Arkell","year":"2022","unstructured":"Arkell TR, et al. Sex differences in acute cannabis effects revisited: results from two randomized, controlled trials. Addict Biol. 2022;27(2): e13125.","journal-title":"Addict Biol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00941-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00941-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00941-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T15:04:20Z","timestamp":1747321460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00941-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00941-8","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"9 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Federal Office of Public Health (BAG, Switzerland): unrestricted grant number 10. 001359\/204.0001\/-738; Departmental Research Grant (Department of Anaesthesiology and Pain Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"WW: Conceptualization, methodology, PK\/ PD modeling, writing\u2014original draft; RG: Conceptualization, investigation, methodology, project administration, supervision, validation, writing\u2014review & editing; LT: Conceptualization, funding acquisition, investigation, methodology; MKB: Conceptualization, investigation, methodology, validation, writing\u2014original draft.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}},{"value":"This study was conducted with ethics committee approval (Cantonal Ethics Committee Bern, approval number KEK 241\u201309) and approval of the relevant authorities (Federal Office of Public Health of the Swiss Confederation, Swissmedic). It was registered at  (registration number ISRCTN53019164). This study was part of a larger trial on pharmacokinetics of intravenous THC.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All volunteers gave written informed consent prior to enrollment.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"All patients gave written informed consent to participate in the study. No identifiable clinical photo of a patient or identifiable patient data are included in the publication. Hence no consent for publication to publish their data is required from individual patients.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on reasonable request and with ethics committee approval and approval of the relevant authorities.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The code for the Phoenix pharmacokinetic pharmacodynamic model can be requested from the corresponding author upon reasonable request.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}